CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer

被引：0
|
作者：
Pesch, Andrea M. [1 ]
Hirsh, Nicole [1 ]
Chandler, Benjamin C. [1 ]
Michmerhuizen, Anna R. [1 ]
Ritter, Cassandra L. [1 ]
Androsiglio, Marlie [1 ]
Wilder-Romans, Kari [1 ]
Liu, Meilan [1 ]
Gersch, Christina L. [1 ]
Larios, Jose M. [1 ]
Rae, James M. [1 ]
Speers, Corey W. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6280
引用
收藏
页数：2
相关论文
共 50 条
  • [21] RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes
    Pesch, Andrea M.
    Hirsh, Nicole H.
    Michmerhuizen, Anna R.
    Jungles, Kassidy M.
    Wilder-Romans, Kari
    Chandler, Benjamin C.
    Liu, Meilan
    Lerner, Lynn M.
    Nino, Charles A.
    Ward, Connor
    Cobain, Erin F.
    Lawrence, Theodore S.
    Pierce, Lori J.
    Rae, James M.
    Speers, Corey W.
    JCI INSIGHT, 2022, 7 (03)
  • [22] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [23] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Janice Lu
    Journal of Hematology & Oncology, 8
  • [24] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [25] Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer
    Lim, Elgene
    Portman, Neil
    Alexandrou, Sarah
    Haupt, Susan
    Haupt, Ygal
    Caldon, Elizabeth
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [27] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [28] Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers
    Pesch, Andrea M.
    Hirsh, Nicole H.
    Chandler, Benjamin C.
    Michmerhuizen, Anna R.
    Ritter, Cassandra L.
    Androsiglio, Marlie P.
    Wilder-Romans, Kari
    Liu, Meilan
    Gersch, Christina L.
    Larios, Jose M.
    Pierce, Lori J.
    Rae, James M.
    Speers, Corey W.
    CLINICAL CANCER RESEARCH, 2020, 26 (24) : 6568 - 6580
  • [29] Mechanisms of CDK4/6 inhibitor resistance in hormone receptor positive metastatic breast cancer: Single institution retrospective analysis
    Lee, Jin Sun
    Yost, Susan
    Cui, Yujie
    Frankel, Paul
    Li, Sierra Min
    Yuan, Yate-Ching
    Morse, Denise
    Wong-Toh, Judy
    Bosserman, Linda
    Mortimer, Joanne
    Yuan, Yuan
    CANCER RESEARCH, 2022, 82 (04)
  • [30] MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
    Portman, Neil
    Chen, Julia
    Lim, Elgene
    FRONTIERS IN ONCOLOGY, 2021, 11
12345